ArticleNature communications2022
De novo biosynthesis of rubusoside and rebaudiosides in engineered yeasts.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 120 citations in OpenAlex.
- Metabolic and transport engineering enable efficient de novo biosynthesis of patchoulol inSynthetic and systems biotechnology · 2026Article
- The dual role of polyethylene glycol-simulated drought stress inPhysiology and molecular biology of plants : an international journal of functional plant biology · 2026Review
- Dual-Enzyme Biocatalytic Synthesis of Novel Rebaudioside M Analogs with Enhanced Aqueous Solubility, Physicochemical Stability, and Sensory Profiles.Foods (Basel, Switzerland) · 2026Article
- Engineered microorganisms unlock a new era of diterpenoid biomanufacturing: recent advances and future perspectives.Bioresources and bioprocessing · 2026Review
- High yield strategies for triterpenoid biosynthesis in cell factories.Journal of microbiology (Seoul, Korea) · 2026Review
- Combining multiple metabolic strategies for efficient production of longifolene inSynthetic and systems biotechnology · 2026Article
- Discovery and engineering of UDP-glycosyltransferase and its applications in natural sweetener glycosylation.World journal of microbiology & biotechnology · 2026Review
- Multi-omics-guided discovery of CYP5035 enables heterologous production and engineering of pachymic acid in yeast.Journal of biological engineering · 2026Article
- Metabolic Engineering ofJournal of fungi (Basel, Switzerland) · 2026Article
- EngineeredJournal of fungi (Basel, Switzerland) · 2026Article
- A Comprehensive Review on Steviol Glycosides: Sources, Properties, Bioactivities, Sensory-Functional Enhancement and Bioproduction Strategies.Plants (Basel, Switzerland) · 2026Review
- Diterpenoids in medicinal plants: structure, distribution, biological activities, biosynthesis, and bioengineering prospects.Frontiers in plant science · 2026Review
- De novo biosynthesis ofBiodesign research · 2025Article
- Integrated genomic and DNA methylome analyses reveal epigenetic regulation of stevia glycoside biosynthesis inHorticulture research · 2025Article
- De novo biosynthesis of Asperosaponin VI inSynthetic and systems biotechnology · 2025Article
- Sustainable Natural Product Glycosylation: A Critical Evaluation of Biocatalytic and Chemical Approaches.ChemSusChem · 2025Review
- Identification, characterization, and application of an NADPH-dependent carbonyl reductase inSynthetic and systems biotechnology · 2025Article
- Regulation and induction of fungal secondary metabolites: a comprehensive review.Archives of microbiology · 2025Review
- High-throughput metabolic engineering ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-sugar diet causes health problems, many of which can be addressed with the use of sugar substitutes. Rubusoside and rebaudiosides are interesting molecules, considered the next generation of sugar substitutes due to their low-calorie, superior sweetness and organoleptic properties. However, their low abundance in nature makes the traditional plant extraction process neither economical nor environmental-friendly. Here we engineer baker's yeast Saccharomyces cerevisiae as a chassis for the de novo production of rubusoside and rebaudiosides. In this process, we identify multiple issues that limit the production, including rate-liming steps, product stress on cellular fitness and unbalanced metabolic networks. We carry out a systematic engineering strategy to solve these issues, which produces rubusoside and rebaudiosides at titers of 1368.6 mg/L and 132.7 mg/L, respectively. The rubusoside chassis strain here constructed paves the way towards a sustainable, large-scale fermentation-based manufacturing of diverse rebaudiosides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.